Angiogenic signaling aberrantly induced by tumor hypoxia

Frontiers in Bioscience

Volumn 16, Issue 1, 2011, Pages 31-48

  Takenaga, Keizo ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Antiangiogenic factor; Bone marrow derived cells; HIF inhibitor; Hypoxia; Hypoxia inducible factor; Proangiogenic factor; Review; Tumor angiogenesis

Indexed keywords

ADRENOMEDULLIN; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 2; CHEMOKINE; CYCLOOXYGENASE 2; ENDOTHELIN; FIBROBLAST GROWTH FACTOR 2; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; MEMBRANE PROTEIN; NITRIC OXIDE SYNTHASE; PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR B; PROTEIN; STEM CELL FACTOR; VASCULOTROPIN A;

ANIMAL; ANOXIA; BONE MARROW CELL; DRUG ANTAGONISM; HUMAN; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; VASCULARIZATION;

ADRENOMEDULLIN; ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-2; ANIMALS; ANOXIA; BONE MARROW CELLS; CHEMOKINES; CYCLOOXYGENASE 2; ENDOTHELINS; FIBROBLAST GROWTH FACTOR 2; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MATRIX METALLOPROTEINASES; MEMBRANE PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREGNANCY PROTEINS; PROTO-ONCOGENE PROTEINS C-SIS; STEM CELL FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955008189     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3674     Document Type: Article

References (180)

1. GN Naumov, LA Akslen, J Folkman: Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5, 1779-1787 (2006) (Pubitemid 44435320)
2. J Folkman, K Watson, D Ingber: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58-61 (1989) (Pubitemid 19115892)
3. P Carmeliet: Mechanisms of angiogenesis and arteriogenesis. Nat Med 6, 389-395 (2006)
4. D Fukumura, RK Jain: Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 74, 72-84 (2007) (Pubitemid 350051025)
5. S Morikawa, P Baluk, T Kaidoh, A Haskell, RK Jain, DM McDonald: Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160, 985-1000 (2002) (Pubitemid 34224587)
6. K Hida, Y Hida, M Shindoh: Understanding tumor endothelial cell abnormalities to develop ideal antiangiogenic therapies. Cancer Sci 99, 459-466 (2008) (Pubitemid 351228561)
7. B Nico, V Benagiano, D Mangieri, N Maruotti, A Vacca, D Ribatti: Evaluation of microvascular density in tumors: pro and contra. Histol Histopathol 23, 601-607 (2008). (Pubitemid 351559267)
8. N Koshikawa, A Iyozumi, M Gassmann, K Takenaga: Constitutive upregulation of hypoxia-inducible factor-1alpha mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure. Oncogene 22, 6717-6724 (2003) (Pubitemid 37372212)
9. K Ishikawa, K Takenaga, M Akimoto, N Koshikawa, A Yamaguchi, H Imanishi, K Nakada, Y Honma, J Hayashi: ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320, 661-664 (2008) (Pubitemid 351928347)
10. GL Semenza: Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 60, 591-597 (2008)
11. J Pouyssegur, F Dayan, NM Mazure: Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441, 437-443 (2006) (Pubitemid 44050138)
12. EB Rankin, AJ Giaccia: The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15, 678-685 (2008) (Pubitemid 351405072)
13. GL Semenza: Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 19, 12-16 (2009)
14. EP Cummins, CT Taylor: Hypoxia-responsive transcription factors. Pflugers Arch 450, 363-371 (2005) (Pubitemid 41380694)
15. H Tian, SL McKnight, DW Russell: Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11:72-82 (1997) (Pubitemid 27043825)
16. Y Makino, R Cao, K Svensson, G Bertilsson, M Asman, H Tanaka, Y Cao, A Berkenstam, L Poellinger: Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414:550-554 (2001) (Pubitemid 33131538)
17. A Taguchi, K Yanagisawa, M Tanaka, K Cao, Y Matsuyama, H Goto, T Takahashi: Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. Cancer Res 68, 5540-5545 (2008)
18. P Secades, JP Rodrigo, M Hermsen, C Alvarez, C Suarez, MD Chiara: Increase in gene dosage is a mechanism of HIF-1alpha constitutive expression in head and neck squamous cell carcinomas. Genes Chromosomes Cancer 48, 441-454 (2009)
19. N Koshikawa, J Hayashi, A Nakagawara, K Takenaga: Reactive oxygen species-generating mitochondrial DNA mutation up-regulates hypoxia-inducible factor-1alpha gene transcription via phosphatidylinositol 3-kinase-Akt/protein kinase C/histone deacetylase pathway. J Biol Chem 284, 33185-33194 (2009)
20. M Nakamura, JM Bodily, M Beglin, S Kyo, M Inoue, LA Laimins: Hypoxia-specific stabilization of HIF-1alpha by human papillomaviruses. Virology 387, 442-448 (2009)
21. YV Liu, GL Semenza: RACK1 vs. HSP90: competition for HIF-1 alpha degradation vs. stabilization. Cell Cycle 6, 656-659 (2007) (Pubitemid 46535675)
22. DR Mole, C Blancher, RR Copley, PJ Pollard, JM Gleadle, J Ragoussis, PJ Ratcliffe: Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 284, 16767-16775 (2009)
23. H Kato, S Tamamizu-Kato, F Shibasaki: Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. J Biol Chem 279, 41966-41974 (2004) (Pubitemid 39313647)
24. SH Bae, JW Jeong, JA Park, SH Kim, MK Bae, SJ Choi, KW Kim: Sumoylation increases HIF-1alpha stability and its transcriptional activity. Biochem Biophys Res Commun 324, 394-400 (2004) (Pubitemid 39311508)
25. A Carbia-Nagashima, J Gerez, C Perez-Castro, M Paez-Pereda, S Silberstein, GK Stalla, F Holsboer, E Arzt: RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell 131, 309-323 (2007) (Pubitemid 47592916)
26. J Cheng, X Kang, S Zhang, ET Yeh: SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 131, 584-95 (2007) (Pubitemid 350007694)
27. I Ader, L Brizuela, P Bouquerel, B Malavaud, O Cuvillier: Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. Cancer Res 68, 8635-8642 (2008)
28. RR Raval, KW Lau, MG Tran, HM Sowter, SJ Mandriota, JL Li, CW Pugh, PH Maxwell, AL Harris, PJ Ratcliffe: Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindauassociated renal cell carcinoma. Mol Cell Biol 25, 5675-5686 (2005) (Pubitemid 40853601)
29. A Franovic, CE Holterman, J Payette, S Lee: Human cancers converge at the HIF-2alpha oncogenic axis. Proc Natl Acad Sci U S A 106, 21306-21311 (2009)
30. NS Chandel, WC Trzyna, DS McClintock, PT Schumacker: Role of oxidants in NF-kappa B activation and TNF-alpha gene transcription induced by hypoxia and endotoxin. J Immunol 165, 1013-1021 (2000) (Pubitemid 30484771)
31. G Gloire, S Legrand-Poels, J Piette: NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 72, 1493-1505 (2006) (Pubitemid 44666727)
32. EP Cummins, E Berra, KM Comerford, A Ginouves, KT Fitzgerald, F Seeballuck, C Godson, JE Nielsen, P Moynagh, J Pouyssegur, CT Taylor: Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci U S A 103, 18154-18159 (2006) (Pubitemid 44871628)
33. J Rius, M Guma, C Schachtrup, K Akassoglou, AS Zinkernagel, V Nizet, RS Johnson, GG Haddad, M Karin: NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 453, 807-811 (2008) (Pubitemid 351793778)
34. RS Belaiba, S Bonello, C Zahringer, S Schmidt, J Hess, T Kietzmann, A Gorlach: Hypoxia up-regulates hypoxiainducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol Biol Cell 18, 4691-4697 (2007) (Pubitemid 350246672)
35. R Roskoski Jr: Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 62, 179-213 (2007) (Pubitemid 46679285)
36. SJ Harper, DO Bates: VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 8, 880-887 (2008)
37. J Grunstein, JJ Masbad, R Hickey, F Giordano, RS Johnson: Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol Cell Biol 20, 7282-7291 (2000)
38. B Li, EE Sharpe, AB Maupin, AA Teleron, AL Pyle, P Carmeliet, PP Young: VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 20,1495-1497 (2006)
39. JA Forsythe, BH Jiang, NV Iyer, F Agani, SW Leung, RD Koos, GL Semenza: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16, 4604-4613 (1996) (Pubitemid 26272112)
40. Z Hua, Q Lv, W Ye, CK Wong, G Cai, D Gu, Y Ji, C Zhao, J Wang, BB Yang, Y Zhang: miRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One 1, e116 (2006)
41. HP Gerber, F Condorelli, J Park, N Ferrara: Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is upregulated by hypoxia. J Biol Chem 272, 23659-23667 (1997) (Pubitemid 27410939)
42. Q Pan, Y Chanthery, WC Liang, S Stawicki, J Mak, N Rathore, RK Tong, J Kowalski, SF Yee, G Pacheco, S Ross, Z Cheng, J Le Couter, G Plowman, F Peale, AW Koch, Y Wu, A Bagri, M Tessier-Lavigne, RJ Watts: Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11, 53-67 (2007) (Pubitemid 46054517)
43. S Lee, TT Chen, CL Barber, MC Jordan, J Murdock, S Desai, N Ferrara, A Nagy, KP Roos, ML Iruela-Arispe: Autocrine VEGF signaling is required for vascular homeostasis. Cell 130, 691-703 (2007) (Pubitemid 47268059)
44. G Thurston, C Suri, K Smith, J McClain, TN Sato, GD Yancopoulos, DM McDonald: Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286, 2511-2514 (1999)
45. PC Maisonpierre, C Suri, PF Jones, S Bartunkova, SJ Wiegand, C Radziejewski, D Compton, J McClain, TH Aldrich, N Papadopoulos, TJ Daly, S Davis, TN Sato, GD Yancopoulos: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277, 55-60 (1997) (Pubitemid 27450643)
46. J Gu, H Yamamoto, M Ogawa, CY Ngan, K Danno, H Hemmi, N Kyo, I Takemasa, M Ikeda, M Sekimoto, M Monden: Hypoxia-induced up-regulation of angiopoietin-2 in colorectal cancer. Oncol Rep 15, 779-783 (2006)
47. L Zhang, N Yang, JW Park, D Katsaros, S Fracchioli, G Cao, A O'Brien-Jenkins, TC Randall, SC Rubin, G Coukos: Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 63, 3403-12 (2003) (Pubitemid 36735901)
48. P Vajkoczy, M Farhadi, A Gaumann, R Heidenreich, R Erber, A Wunder, JC Tonn, MD Menger, G Breier: Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest 109, 777-785 (2002) (Pubitemid 34263154)
49. IB Lobov, PC Brooks, RA Lang: Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 99, 11205-11210 (2002) (Pubitemid 34920903)
50. OH Lee, J Xu, J Fueyo, MM Alonso, D Liu, V Martin, H Jiang, Y Piao, TJ Liu, C Gomez-Manzano: Angiopoietin-2 decreases vascular endothelial growth factor expression by modulating HIF-1 alpha levels in gliomas. Oncogene 27, 1310-4 (2008) (Pubitemid 351294682)
51. MP Simon, R Tournaire, J Pouyssegur: The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1. J Cell Physiol 217, 809-18 (2008)
52. Y Hasegawa, M Abe, T Yamazaki, O Niizeki, K Shiiba, I Sasaki, Y Sato: Transcriptional regulation of human angiopoietin-2 by transcription factor Ets-1. Biochem Biophys Res Commun 316, 52-58 (2004) (Pubitemid 38299127)
53. M Oikawa, M Abe, H Kurosawa, W Hida, K Shirato, Y Sato: Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1. Biochem Biophys Res Commun 289, 39-43 (2001) (Pubitemid 33108788)
54. P Guo, B Hu, W Gu, L Xu, D Wang, HJ Huang, WK Cavenee, SY Cheng: Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 162, 1083-1093 (2003) (Pubitemid 36350654)
55. D Yoshida, K Kim, M Noha, A Teramoto: Hypoxia inducible factor 1-alpha regulates of platelet derived growth factor-B in human glioblastoma cells. J Neurooncol 76, 13-21 (2006) (Pubitemid 43115754)
56. E Ulleras, A Wilcock, SJ Miller, GC Franklin: The sequential activation and repression of the human PDGF-B gene during chronic hypoxia reveals antagonistic roles for the depletion of oxygen and glucose. Growth Factors 19, 233-245 (2001) (Pubitemid 34071670)
57. C Parr, G Watkins, M Boulton, J Cai, WG Jiang: Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer 41, 2819-2827 (2005) (Pubitemid 41713119)
58. L Zhang, J Chen, Y Ke, RE Mansel, WG Jiang: Expression of placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol 3, 68-79 (2005)
59. M Cramer, I Nagy, BJ Murphy, M Gassmann, MO Hottiger, O Georgiev, W Schaffner: NF-kappaB contributes to transcription of placenta growth factor and interacts with metal responsive transcription factor-1 in hypoxic human cells. Biol Chem 386, 865-872 (2005) (Pubitemid 41448142)
60. N Patel, CS Gonsalves, P Malik, VK Kalra: Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxia-inducible factor-1 alpha. Blood 112, 856-865 (2008)
61. M Calvani, A Rapisarda, B Uranchimeg, RH Shoemaker, G Melillo: Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 107, 2705-2712 (2006)
62. ZB Han, H Ren, H Zhao, Y Chi, K Chen, B Zhou, YJ Liu, L Zhang, B Xu, B Liu, R Yang, ZC Han: Hypoxiainducible factor (HIF)-1 alpha directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF).Carcinogenesis 29, 1853-1861 (2008)
63. L Sun, AM Hui, Q Su, A Vortmeyer, Y Kotliarov, S Pastorino, A Passaniti, J Menon, J Walling, R Bailey, M Rosenblum, T Mikkelsen, HA Fine: Neuronal and gliomaderived stem cell factor induces angiogenesis within the brain. Cancer Cell 9, 287-300 (2006)
64. J Matsui, T Wakabayashi, M Asada, K Yoshimatsu, M Okada: Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells. J. Biol. Chem 279, 18600-18607 (2004) (Pubitemid 38623281)
65. B Heissig, Z Werb, S Rafii, K Hattori: Role of c-kit/Kit ligand signaling in regulating vasculogenesis. Thromb Haemost 90, 570-576 (2003) (Pubitemid 37287623)
66. J Litz, GW Krystal: Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol Cancer Ther 5, 1415-1422 (2006) (Pubitemid 44070477)
67. PY Wai, PC Kuo: The role of Osteopontin in tumor metastasis. J Surg Res 121, 228-241 (2004) (Pubitemid 39387464)
68. Y Zhu, DT Denhardt, H Cao, PD Sutphin, AC Koong, AJ Giaccia, QT Le: Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene 24:6555-6563 (2005) (Pubitemid 41486638)
69. LL Nikitenko, SB Fox, S Kehoe, MC Rees, R Bicknell: Adrenomedullin and tumour angiogenesis. Br J Cancer 94, 1-7 (2006) (Pubitemid 43088532)
70. S Fernandez-Sauze, C Delfino, K Mabrouk, C Dussert, O Chinot, PM Martin, F Grisoli, L Ouafik, F Boudouresque: Effects of adrenomedullin on endothelial cells in the multistep process of angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors. Int J Cancer 108, 797-804 (2004) (Pubitemid 38112605)
71. T Iwase, N Nagaya, T Fujii, T Itoh, H Ishibashi-Ueda, M Yamagishi, K Miyatake, T Matsumoto, S Kitamura, K Kangawa: Adrenomedullin enhances angiogenic potency of bone marrow transplantation in a rat model of hindlimb ischemia. Circulation 111, 356-362 (2005) (Pubitemid 40165344)
72. Y Fujita, H Mimata, N Nasu, T Nomura, Y Nomura, M Nakagawa: Involvement of adrenomedullin induced by hypoxia in angiogenesis in human renal cell carcinoma. Int J Urol 9, 285-295 (2002) (Pubitemid 34779711)
73. M Garayoa, A Martínez, S Lee, R Pio, WG An, L Neckers, J Trepel, LM Montuenga, H Ryan, R Johnson, M Gassmann, F Cuttitta: Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol 14, 848-862 (2000) (Pubitemid 32260498)
74. LL Nikitenko, DM Smith, R Bicknell, MC Rees:Transcriptional regulation of the CRLR gene in human microvascular endothelial cells by hypoxia. FASEB J 17, 1499-1501 (2003)
75. MJ Grimshaw: Endothelins and hypoxia-inducible factor in cancer. Endocr Relat Cancer 14, 233-244 (2007) (Pubitemid 47242625)
76. A Bagnato, F Spinella, L Rosano: The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol 86, 473-84 (2008)
77. MJ Grimshaw: Endothelins and hypoxia-inducible factor in cancer. Endocr Relat Cancer 14, 233-244 (2007) (Pubitemid 47242625)
78. F Spinella, L Rosano, V Di Castro, PG Natali, A Bagnato: Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J Biol Chem 277, 27850-27855 (2002) (Pubitemid 34966730)
79. G Serini, F Maione, E Giraudo, F Bussolino: Semaphorins and tumor angiogenesis. Angiogenesis 12, 187-193 (2009)
80. P Conrotto, D Valdembri, S Corso, G Serini, L Tamagnone, PM Comoglio, F Bussolino, S Giordano: Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 105, 4321-4329 (2005) (Pubitemid 40720778)
81. JR Basile, RM Castilho, VP Williams, JS Gutkind: Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis. Proc Natl Acad Sci U S A 103, 9017-9022 (2006) (Pubitemid 43902525)
82. JR Sierra, S Corso, L Caione, V Cepero, P Conrotto, A Cignetti, W Piacibello, A Kumanogoh, H Kikutani, PM Comoglio, L Tamagnone, S Giordano: Tumor angiogenesis and progression are enhanced by Sema4D produced by tumorassociated macrophages. J Exp Med 205, 1673-1685 (2008) (Pubitemid 351962030)
83. Q Sun, H Zhou, NO Binmadi, JR Basile: Hypoxiainducible factor-1-mediated regulation of semaphorin 4D affects tumor growth and vascularity. J Biol Chem 284, 32066-32074 (2009)
84. DP Toomey, JF Murphy, KC Conlon: COX-2, VEGF and tumour angiogenesis. Surgeon 7, 174-180 (2009)
85. M Tsujii, S Kawano, S Tsuji, H Sawaoka, M Hori, RN DuBois: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93, 705-716 (1998) (Pubitemid 28257578)
86. SP Huang, MS Wu, CT Shun, HP Wang, CY Hsieh, ML Kuo, JT Lin: Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. J Biomed Sci 12, 229-241 (2005)
87. A Kaidi, D Qualtrough, AC Williams, C Paraskeva: Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxiainducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res 66, 6683-6691 (2006) (Pubitemid 44085625)
88. JF Schmedtje Jr, YS Ji, WL Liu, RN DuBois, MS Runge: Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 272, 601-608 (1997) (Pubitemid 27021200)
89. R Roy, J Yang, MA Moses: Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27, 5287-5297 (2009)
90. Y Ben-Yosef, N Lahat, S Shapiro, H Bitterman, A Miller: Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation. Circ Res 90, 784-791 (2002) (Pubitemid 34633894)
91. Y Miyazaki, A Hara, K Kato, T Oyama, Y Yamada, H Mori, T Shibata: The effect of hypoxic microenvironment on matrix metalloproteinase expression in xenografts of human oral squamous cell carcinoma. Int J Oncol 32, 145-151 (2008) (Pubitemid 351176072)
92. BL Petrella, J Lohi, CE Brinckerhoff: Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene 24, 1043-1052 (2005) (Pubitemid 40313881)
93. QX Sang: Complex role of matrix metalloproteinases in angiogenesis. Cell Res 8, 171-177 (1998) (Pubitemid 128544277)
94. S Ulisse, E Baldini, S Sorrenti, M D'Armiento: The urokinase plasminogen activator system: a target for anticancer therapy. Curr Cancer Drug Targets 9, 32-71 (2009)
95. H Liao, MC Hyman, DA Lawrence, DJ Pinsky: Molecular regulation of the PAI-1 gene by hypoxia: contributions of Egr-1, HIF-1alpha, and C/EBPalpha. FASEB J 21, 935-949 (2007) (Pubitemid 46348266)
96. K Bajou, H Peng, WE Laug, C Maillard, A Noel, JM Foidart, JA Martial, YA DeClerck: Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell 14, 324-334 (2008)
97. L Morbidelli, S Donnini, M Ziche: Role of nitric oxide in the modulation of angiogenesis. Curr Pharm Des 9, 521-530 (2003) (Pubitemid 36221720)
98. ER Cullis, TL Kalber, SE Ashton, JE Cartwright, JR Griffiths, AJ Ryan, SP Robinson: Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126. Microvasc Res 71, 76-84 (2006)
99. JP Cooke: NO and angiogenesis. Atheroscler Suppl 4, 53-60 (2003) (Pubitemid 38234495)
100. F Coulet, S Nadaud, M Agrapart, F Soubrier: Identification of hypoxia-response element in the human endothelial nitric-oxide synthase gene promoter. J Biol Chem 278, 46230-46240 (2003) (Pubitemid 37452193)
101. BA Teicher: Newer vascular targets: endosialin (review). Int J Oncol 30, 305-312 (2007)
102. RG Bagley, N Honma, W Weber, P Boutin, C Rouleau, S Shankara, S Kataoka, I Ishida, BL Roberts, BA Teicher: Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization. Microvasc Res 76, 180-188 (2008)
103. RG Bagley, C Rouleau, T St Martin, P Boutin, W Weber, M Ruzek, N Honma, M Nacht, S Shankara, S Kataoka, I Ishida, BL Roberts, BA Teicher: Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248. Mol Cancer Ther 7, 2536-2546 (2008)
104. A Ohradanova, K Gradin, M Barathova, M Zatovicova, T Holotnakova, J Kopacek, S Parkkila, L Poellinger, S Pastorekova, J Pastorek: Hypoxia upregulates expression of human endosialin gene via hypoxia-inducible factor 2. Br J Cancer 99, 1348-1356 (2008)
105. MV Sitkovsky, J Kjaergaard, D Lukashev, A Ohta: Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 14, 5947-5952 (2008)
106. MF Ethier, V Chander, JG Dobson Jr: Adenosine stimulates proliferation of human endothelial cells in culture. Am J Physiol 265, H131-H138 (1993) (Pubitemid 23224700)
107. I Feoktistov, AE Goldstein, S Ryzhov, D Zeng, L Belardinelli, T Voyno-Yasenetskaya, I Biaggioni: Differential expression of adenosine receptors in human endothelial cells: Role of A2B receptors in angiogenic factor regulation. Circ Res 90, 531-538 (2002) (Pubitemid 34640902)
108. A Ahmad, S Ahmad, L Glover, SM Miller, JM Shannon, X Guo, WA Franklin, JP Bridges, JB Schaack, SP Colgan, CW White: Adenosine A2A receptor is a unique angiogenic target of HIF-2alpha in pulmonary endothelial cells. Proc Natl Acad Sci U S A 106, 10684-10689 (2009)
109. K Kuwabara, M Matsumoto, J Ikeda, O Hori, S Ogawa, Y Maeda, K Kitagawa, N Imuta, T Kinoshita, DM Stern, H Yanagi, T Kamada: Purification and characterization of a novel stress protein, the 150-kDa oxygen-regulated protein (ORP150), from cultured rat astrocytes and its expression in ischemic mouse brain. J Biol Chem 271, 5025-5032 (1996)
110. K Ozawa, Y Tsukamoto, O Hori, Y Kitao, H Yanagi, DM Stern, S Ogawa: Regulation of tumor angiogenesis by oxygen-regulated protein 150, an inducible endoplasmic reticulum chaperone. Cancer Res 61, 4206-4213 (2001) (Pubitemid 32720990)
111. Y Tsukamoto, K Kuwabara, S Hirota, J Ikeda, D Stern, H Yanagi, M Matsumoto, S Ogawa, Y Kitamura: 150-kD oxygen-regulated protein is expressed in human atherosclerotic plaques and allows mononuclear phagocytes to withstand cellular stress on exposure to hypoxia and modified low density lipoprotein. J Clin Invest 98, 1930-1941 (1996) (Pubitemid 26359211)
112. I Kryczek, S Wei, E Keller, R Liu, W Zou: Stromal derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 292, C987-C995 (2006)
113. I Petit, D Jin, S Rafii: The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 28, 299-307 (2007) (Pubitemid 46963141)
114. T Schioppa, B Uranchimeg, A Saccani, SK Biswas, A Doni, A Rapisarda, S Bernasconi, S Saccani, M Nebuloni, L Vago, A Mantovani, G Melillo, A Sica: Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198, 1391-1402 (2003) (Pubitemid 37392484)
115. I Kryczek, A Lange, P Mottram, X Alvarez, P Cheng, M Hogan, L Moons, S Wei, L Zou, V Machelon, D Emilie, M Terrassa, A Lackner, TJ Curiel, P Carmeliet, W Zou: CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 65, 465-472 (2005)
116. DJ Ceradini, AR Kulkarni, MJ Callaghan, OM Tepper, N Bastidas, ME Kleinman, JM Capla, RD Galiano, JP Levine, GC Gurtner: Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10, 858-864 (2004) (Pubitemid 39070860)
117. N Mukaida: Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. Int J Hematol 72, 391-398 (2000)
118. C Charalambous, LB Pen, YS Su, J Milan, TC Chen, FM Hofman: Interleukin-8 differentially regulates migration of tumor-associated and normal human brain endothelial cells. Cancer Res 65, 10347-10354 (2005) (Pubitemid 41743727)
119. I Desbaillets, AC Diserens, N Tribolet, MF Hamou, EG Van Meir: Upregulation of interleukin 8 by oxygendeprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med 186, 1201-1212 (1997) (Pubitemid 27469015)
120. M Wysoczynski, DM Shin, M Kucia, MZ Ratajczak: Selective upregulation of interleukin-8 by human rhabdomyosarcomas in response to hypoxia: therapeutic implications. Int J Cancer 126, 371-381 (2010)
121. M Kunz, A Hartmann, E Flory, A Toksoy, D Koczan, HJ Thiesen, N Mukaida, M Neumann, UR Rapp, EB Broker, R Gillitzer: Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism for high tumor aggressiveness. Am J Pathol 155, 753-763 (1999) (Pubitemid 29426821)
122. KS Kim, V Rajagopal, C Gonsalves, C Johnson, VK Kalra: A novel role of hypoxia-inducible factor in cobalt chloride-and hypoxia-mediated expression of IL-8 chemokine in human endothelial cells. J Immunol 177, 7211-7224 (2006) (Pubitemid 44715090)
123. DA Chan, TL Kawahara, PD Sutphin, HY Chang, JT Chi, AJ Giaccia: Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 15, 527-538 (2009)
124. D Martin, R Galisteo, JS Gutkind: CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 284, 6038-6042 (2009)
125. M Li, Y Zhang, LW Feurino, H Wang, WE Fisher, FC Brunicardi, C Chen, Q Yao: Interleukin-8 increases vascular endothelial growth factor and neuropilin expression and stimulates ERK activation in human pancreatic cancer. Cancer Sci 99, 733-737 (2008) (Pubitemid 351448077)
126. R Salcedo, HA Young, ML Ponce, JM Ward, HK Kleinman, WJ Murphy, JJ Oppenheim: Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J Immunol 166, 7571-7578 (2001) (Pubitemid 32525638)
127. C Combadiere, SK Ahuja, PM Murphy: Cloning and functional expression of a human eosinophil CC chemokine receptor. J Biol Chem 270, 16491-16494 (1995)
128. V Levina, BM Nolen, AM Marrangoni, P Cheng, JR Marks, MJ Szczepanski, ME Szajnik, E Gorelik, AE Lokshin: Role of eotaxin-1 signaling in ovarian cancer. Clin Cancer Res 15, 2647-2656 (2009)
129. D Wagsater, S Lofgren, A Hugander, O Dienus, J Dimberg: Analysis of single nucleotide polymorphism in the promoter and protein expression of the chemokine eotaxin-1 in colorectal cancer patients. World J Surg Oncol 5, 84 (2007)
130. SB Early, K Hise, JK Han, L Borish, JW Steinke: Hypoxia stimulates inflammatory and fibrotic responses from nasal-polyp derived fibroblasts. Laryngoscope 117, 511-515 (2007) (Pubitemid 46407764)
131. R van Horssen, AM Eggermont, TL ten Hagen: Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes. Cytokine Growth Factor Rev 17, 339-348 (2006) (Pubitemid 44572878)
132. G Barnett, AM Jakobsen, M Tas, K Rice, J Carmichael, JC Murray: Prostate adenocarcinoma cells release the novel proinflammatory polypeptide EMAP-II in response to stress. Cancer Res 60, 2850-2857 (2000) (Pubitemid 30395805)
133. Y Hou, PA Plett, DA Ingram, G Rajashekhar, CM Orschell, MC Yoder, KL March, M Clauss: Endothelialmonocyte-activating polypeptide II induces migration of endothelial progenitor cells via the chemokine receptor CXCR3. Exp Hematol 34, 1125-1132 (2006) (Pubitemid 44080393)
134. S Matschurat, UE Knies, V Person, L Fink, B Stoelcker, C Ebenebe, HA Behrensdorf, J Schaper, M Clauss: Regulation of EMAP II by hypoxia. Am J Pathol 162, 93-103 (2003) (Pubitemid 36041992)
135. AT Tandle, M Calvani, B Uranchimeg, D Zahavi, G Melillo, SK Libutti: Endothelial monocyte activating polypeptide-II modulates endothelial cell responses by degrading hypoxia-inducible factor-1alpha through interaction with PSMA7, a component of the proteasome. Exp Cell Res 315, 1850-1859 (2009)
136. SJ Harper, DO Bates: VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 8, 880-887 (2008)
137. DO Bates, TG Cui, JM Doughty, M Winkler, M Sugiono, JD Shields, D Peat, D Gillatt, SJ Harper: VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 62, 4123-4131 (2002) (Pubitemid 34791084)
138. J Woolard, WY Wang, HS Bevan, Y Qiu, L Morbidelli, RO Pritchard-Jones, TG Cui, M Sugiono, E Waine, R Perrin, R Foster, J Digby-Bell, JD Shields, CE Whittles, RE Mushens, DA Gillatt, M Ziche, SJ Harper, DO Bates: VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 64, 7822-7835 (2004) (Pubitemid 39446915)
139. ES Rennel, MA Hamdollah-Zadeh, ER Wheatley, A Magnussen, Y Schuler, SP Kelly, C Finucane, D Ellison, S Cebe-Suarez, K Ballmer-Hofer, S Mather, L Stewart, DO Bates, SJ Harper: Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. Eur J Cancer 44, 1883-1894 (2008)
140. AH Varey, ES Rennel, Y Qiu, HS Bevan, RM Perrin, S Raffy, AR Dixon, C Paraskeva, O Zaccheo, AB Hassan, SJ Harper, DO Bates: VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro-and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer 98, 1366-1379 (2008) (Pubitemid 351543576)
141. DG Nowak, EM Amin, ES Rennel, C Hoareau-Aveilla, M Gammons, G Damodoran, M Hagiwara, SJ Harper, J Woolard, MR Ladomery, DO Bates: Regulation of vascular
142. DG Nowak, J Woolard, EM Amin, O Konopatskaya, MA Saleem, AJ Churchill, MR Ladomery, SJ Harper, DO Bates: Expression of pro-and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci 121, 3487-3495 (2008)
143. NS Patel, JL Li, D Generali, R Poulsom, DW Cranston, AL Harris: Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 65, 8690-8697 (2005) (Pubitemid 41377356)
144. M Hellstrom, LK Phng, JJ Hofmann, E Wallgard, L Coultas, P Lindblom, J Alva, AK Nilsson, L Karlsson, N Gaiano, Yoon K, Rossant J, Iruela-Arispe ML, Kalen M, Gerhardt H, Betsholtz C: Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445, 776-780 (2007) (Pubitemid 46279716)
145. JL Li, AL Harris: Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front Biosci 14, 3094-3110 (2009)
146. NW Gale, MG Dominguez, I Noguera, L Pan, V Hughes, DM Valenzuela, AJ Murphy, NC Adams, HC Lin, J Holash, G Thurston, GD Yancopoulos: Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U S A 101, 15949-15954 (2004) (Pubitemid 39507907)
147. CK Williams, JL Li, M Murga, AL Harris, G Tosato: Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107, 931-939 (2006) (Pubitemid 43156289)
148. J Ridgway, G Zhang, Y Wu, S Stawicki, WC Liang, Y Chanthery, J Kowalski, RJ Watts, C Callahan, I Kasman, M Singh, M Chien, C Tan, JA Hongo, F de Sauvage, G Plowman, M Yan: Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444, 1083-1087 (2006) (Pubitemid 46018529)
149. I Noguera-Troise, C Daly, NJ Papadopoulos, S Coetzee, P Boland, NW Gale, HC Lin, GD Yancopoulos, G Thurston: Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444, 1032-1037 (2006) (Pubitemid 46018516)
150. K Watanabe, Y Hasegawa, H Yamashita, K Shimizu, Y Ding, M Abe, H Ohta, K Imagawa, K Hojo, H Maki, H Sonoda, Y Sato: Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest 114, 898-907 (2004) (Pubitemid 39578717)
151. Y Sato, H Sonoda: The vasohibin family: a negative regulatory system of angiogenesis genetically programmed in endothelial cells. Arterioscler Thromb Vasc Biol 27, 37-41 (2007) (Pubitemid 46360378)
152. T Hosaka, H Kimura, T Heishi, Y Suzuki, H Miyashita, H Ohta, H Sonoda, T Moriya, S Suzuki, T Kondo, Y Sato: Vasohibin-1 expression in endothelium of tumor blood vessels regulates angiogenesis. Am J Pathol 175, 430-439 (2009)
153. M Detmar: The role of VEGF and thrombospondins in skin angiogenesis. J Dermatol Sci 24, S78-84 (2000) (Pubitemid 32008465)
154. KR Laderoute, RM Alarcon, MD Brody, JM Calaoagan, EY Chen, AM Knapp, Z Yun, NC Denko, AJ Giaccia: Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clin Cancer Res 6, 2941-2950 (2000) (Pubitemid 30482137)
155. S Aparicio, S Sawant, N Lara, CJ Barnstable, J Tombran-Tink: Expression of angiogenesis factors in human umbilical vein endothelial cells and their regulation by PEDF. Biochem Biophys Res Commun 326, 387-394 (2005) (Pubitemid 39593559)
156. CJ Hu, SD Chen, DI Yang, TN Lin, CM Chen, TH Huang, CY Hsu: Promoter region methylation and reduced expression of thrombospondin-1 after oxygen-glucose deprivation in murine cerebral endothelial cells. J Cereb Blood Flow Metab 26, 1519-1526 (2006) (Pubitemid 44809081)
157. Y Jin, X An, Z Ye, B Cully, J Wu, J Li: RGS5, a hypoxia-inducible apoptotic stimulator in endothelial cells. J Biol Chem 284, 23436-23443 (2009)
158. C Murdoch, M Muthana, SB Coffelt, CE Lewis: The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8, 618-631 (2008)
159. C Bailey, R Negus, A Morris, P Ziprin, R Goldin, P Allavena, D Peck, A Darzi: Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin Exp Metastasis 24, 121-130 (2007) (Pubitemid 46669245)
160. C Murdoch, A Giannoudis, CE Lewis: Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104, 2224-2234 (2004) (Pubitemid 39331817)
161. JR White, RA Harris, SR Lee, MH Craigon, K Binle, T Price, GL Beard, CR Mundy, S Naylor: Genetic amplification of the transcriptional response to hypoxia as a novel means of identifying regulators of angiogenesis. Genomics 83, 1-8 (2004) (Pubitemid 37518254)
162. HY Fang, R Hughes, C Murdoch, SB Coffelt, SK Biswas, AL Harris, RS Johnson, HZ Imityaz, MC Simon, E Fredlund, FR Greten, J Rius, CE Lewis: Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia. Blood 114, 844-859 (2009)
163. KS Siveen, G Kuttan: Role of macrophages in tumour progression. Immunol Lett 123, 97-102 (2009)
164. MA Venneri, M De Palma, M Ponzoni, F Pucci, C Scielzo, E Zonari, R Mazzieri, C Doglioni, L Naldini: Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 109, 5276-5285 (2007) (Pubitemid 46890548)
165. M De Palma, C Murdoch, MA Venneri, L Naldini, CE Lewis: Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 28, 519-524 (2007)
166. C Murdoch, S Tazzyman, S Webster, CE Lewis. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol 178, 7405-7411 (2007) (Pubitemid 46847468)
167. CE Lewis, M De Palma, L Naldini: Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res 67, 8429-8432 (2007) (Pubitemid 47437413)
168. FR Balkwill: Tumour necrosis factor and cancer. Prog Growth Factor Res 4, 121-137 (1992)
169. DK Jin, K Shido, HG Kopp, I Petit, SV Shmelkov, LM Young, AT Hooper, H Amano, ST Avecilla, B Heissig, K Hattori, F Zhang, DJ Hicklin, Y Wu, Z Zhu, A Dunn, H Salari, Z Werb, NR Hackett, RG Crystal, D Lyden, S Rafii: Cytokinemediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 12, 557-567 (2006)
170. R Du, KV Lu, C Petritsch, P Liu, R Ganss, E Passegue, H Song, S Vandenberg, RS Johnson, Z Werb, G Bergers: HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13, 206-220 (2008) (Pubitemid 351318372)
171. YT Ding, S Kumar, DC Yu: The role of endothelial progenitor cells in tumour vasculogenesis. Pathobiology 75, 265-273 (2008)
172. B Li, EE Sharpe, AB Maupin, AA Teleron, AL Pyle, P Carmeliet, PP Young: VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 20, 1495-1497 (2006)
173. MC Yoder, DA Ingram: The definition of EPCs and other bone marrow cells contributing to neoangiogenesis and tumor growth: is there common ground for understanding the roles of numerous marrow-derived cells in the neoangiogenic process? Biochim Biophys Acta 1796, 50-54 (2009)
174. S Patiar, AL Harris: Role of hypoxia-inducible factor-1alpha as a cancer therapy target. Endocr Relat Cancer 13, S61-75 (2006) (Pubitemid 46219249)
175. GL Semenza: HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. Curr Pharm Des 15, 3839-3843 (2009)
176. H Zhang, DZ Qian, YS Tan, K Lee, P Gao, YR Ren, S Rey, H Hammers, D Chang, R Pili, CV Dang, JO Liu, Semenza GL: Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A 105, 19579-19586 (2008)
177. K Lee, DZ Qian, S Rey, H Wei, JO Liu, GL Semenza: Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci U S A 106, 2353-2358 (2009)
178. K Lee, H Zhang, DZ Qian, S Rey, JO Liu, GL Semenza: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci U S A 106, 17910-17915 (2009)
179. M Paez-Ribes, E Allen, J Hudock, T Takeda, H Okuyama, F Vinals, M Inoue, G Bergers, D Hanahan, O Casanovas: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231 (2009)
180. JM Ebos, CR Lee, W Cruz-Munoz, GA Bjarnason, JG Christensen, RS Kerbel: Accelerated metastasis after shortterm treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239 (2009)